Those who have not received the Pfizer or AZ vaccines face a ‘significantly increased’ risk of blood clots.


Those who have not received the Pfizer or AZ vaccines face a ‘significantly increased’ risk of blood clots.

A CORORONAVIRUS breakthrough has been reached, with experts from the University of Oxford publishing a key study revealing that contracting COVID-19 carries a much higher risk of blood clotting than both the Pfizer and AstraZeneca vaccines.

The findings, which were based on data from more than 29 million people, revealed that there is still a risk after receiving the vaccine – but it is “considerably higher” among people who had the virus. The University of Oxford researchers are completely separate from the AstraZeneca team that developed the vaccine. It comes after the AstraZeneca vaccination was limited in a number of nations earlier this year due to increased concerns.

The latest study, which was published in the British Medical Journal, discovered that there were rare incidences of hospitalization or death from blood clots during brief time intervals after the first dose.

Importantly, they discovered that the probability of these adverse effects is significantly larger and lasts for a longer period of time after coronavirus infection.

“People should be aware of these increased risks after COVID-19 vaccination and seek medical attention promptly if they develop symptoms,” said Julia Hippisley-Cox, the paper’s lead author. “They should also be aware that the risks are significantly higher and over longer periods of time if they become infected with SARS-CoV-2.”

All of the COVID-19 vaccines now available have been examined in randomized clinical trials, which are unlikely to be big enough to discover extremely rare side events.

When rare incidents are discovered, regulators do a risk-benefit analysis of the medicine, weighing the danger of an adverse reaction like a blood clot against the benefits of preventing the condition.

The researchers used routinely obtained electronic health information to assess the short-term hazards of hospital admission from blood clots (within 28 days).

Between December 1, 2020, and April 24, 2021, they collected data from around England.

“This research is essential since many other studies, while valuable, have been constrained by small numbers and potential biases,” Professor Hippisley-Cox remarked.

“We used electronic healthcare records, which contain complete details of immunizations, infections, outcomes, and confounders, to do a robust review of these vaccines and compare them to the hazards associated with COVID-19 infection.”

Concerns about blood clotting events linked to the were highlighted in March. “Brinkwire News in Condensed Form.”


Comments are closed.